Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study
Momar Diouf, Benoist Chibaudel, Thomas Filleron, Christophe Tournigand, Marine Hug de Larauze, Marie-Line Garcia-Larnicol, Sarah Dumont, Christophe Louvet, Nathalie Perez-Staub, Alexandra Hadengue, Aimery de Gramont, Franck Bonnetain, Momar Diouf, Benoist Chibaudel, Thomas Filleron, Christophe Tournigand, Marine Hug de Larauze, Marie-Line Garcia-Larnicol, Sarah Dumont, Christophe Louvet, Nathalie Perez-Staub, Alexandra Hadengue, Aimery de Gramont, Franck Bonnetain
Abstract
Background: Health-related quality of life (QoL) has prognostic value in many cancers. A recent study found that the performance of prognostic systems for metastatic colorectal cancer (mCRC) were improvable. We evaluated the independent prognostic value of QoL for overall survival (OS) and its ability to improve two prognostic systems'performance (Köhne and GERCOR models) for patients with mCRC.
Methods: The EQ-5D questionnaire was self-completed before randomization in the OPTIMOX1, a phase III trial comparing two strategies of FOLFOX chemotherapy which included 620 previously untreated mCRC patients recruited from January 2000 to June 2002 from 56 institutions in five countries. The improvement in models' performance (after addition of QoL) was studied with Harrell's C-index and the net reclassification improvement.
Results: Of the 620 patients, 249 (40%) completed QoL datasets. The Köhne model could be improved by LDH, mobility and pain/discomfort; the C-index rose from 0.54 to 0.67. The associated NRI for 12-month death was 0.23 [0.05; 0.46]. Mobility and pain/discomfort could be added to the GERCOR model: the C-index varied from 0.63 to 0.68. The NRI for 12 months death was 0.35 [0.12; 0.44].
Conclusions: Mobility and pain dimensions of EQ5D are independent prognostic factors and could be useful for staging and treatment assignment of mCRC patients. Presented at the 2011 ASCO Annual Meeting (#3632).
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4029890/bin/1477-7525-12-69-1.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4029890/bin/1477-7525-12-69-2.jpg)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4029890/bin/1477-7525-12-69-3.jpg)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4029890/bin/1477-7525-12-69-4.jpg)
References
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107.
- Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol. 2007;13(28):3806–3815.
- Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311–1319. doi: 10.1093/annonc/mdi246.
- Jessup JM, Gunderson LL, Greene FL, Washington MK, Compton CC, Sobin LH, Minsky B, Goldbert RM, Hamilton SR. Staging System for Colon and Rectal Carcinoma. Ann Surg Oncol. 2010;2011(18):1513–1517.
- Köhne CH, Cunningham D, Di Constanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13(2):308–317. doi: 10.1093/annonc/mdf034.
- Chibaudel B, Bonnetain F, Tournigand C, Bengrine-Lefevre L, Teixeira L, Artru P, Desramé J, Larsen AK, André T, Louvet C, de Gramont A. Simplified prognostic model in patients with oxaliplatin-based or irinoecan-based first-line chemotherapy for metastatic colorectal cancer: A GERCOR study. Oncologist. 2011;16(9):1228–1238. doi: 10.1634/theoncologist.2011-0039.
- Harrell FE, Lee KL, Mark DB. Tutorial in biostatistics. Multivariable prognostic models issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>;2-4.
- Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009;7:102. doi: 10.1186/1477-7525-7-102.
- Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, Osoba D, Bjordal K, Bottomley A. EORTC Clinical Groups. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10:865–871. doi: 10.1016/S1470-2045(09)70200-1.
- Diouf M, Filleron T, Barbare JC, Fin L, Picard C, Bouché O, Dahan L, Paoletti X, Bonnetain F. The added value of quality of life (QoL) for prognoses of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol. 2013;58:509–521. doi: 10.1016/j.jhep.2012.11.019.
- Braun DP, Gupta D, Grutsch JF, Staren ED. Can changes in health related quality of life scores predict survival in stage III and IV colorectal cancer? Qual Life Res. 2011;9:62.
- Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D, Tampellini M, Bottomley A, Garufi C, Focan C, Giacchetti S, Lévi F. Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. Validation of patient’s self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2008;26:2020–2026. doi: 10.1200/JCO.2007.12.3117.
- Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol. 2006;24:394–400. doi: 10.1200/JCO.2005.03.0106.
- Group EQ. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
- Schemper M. Predictive accuracy and explained variation. Stat Med. 2003;22:2299–2308. doi: 10.1002/sim.1486.
- Pencina MJ, D’Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11–21. doi: 10.1002/sim.4085.
- CLARK TG, Altman DG. Developing a prognostic model in presence of missing data: an ovarian cancer study. J Clin Epidemiol. 2003;56:28–37. doi: 10.1016/S0895-4356(02)00539-5.
- Marshall M, Altman DG, Royston P, Holder RL. Comparaison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study. BMC Med Res Methodol. 2010;10:7. doi: 10.1186/1471-2288-10-7.
- Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681–694. doi: 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>;2-R.
- Marshall M, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol. 2009;9:57. doi: 10.1186/1471-2288-9-57.
- Tournoux-Facon C, Paoletti X, Barbare JC, Bouché O, Rougier P, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Bedenne L, Bonnetain F. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol. 2011;54(1):108–114. doi: 10.1016/j.jhep.2010.06.015.
- Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481. doi: 10.1080/01621459.1958.10501452.
- Mauer M, Bottomley A, Coens C, Gotay C. Prognostic factor analysis of health-related quality of life data in cancer: statistical methodological evaluation. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):179–196. doi: 10.1586/14737167.8.2.179.
- Vach W, Blettner M. Encyclopedia of Biostatistics. New York: John Wiley & Sons; 1998. Missing data in epidemiologic studies; pp. 2641–2654.
- Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? Br Med J. 2009;338:b375. doi: 10.1136/bmj.b375. 1317-1320.
Source: PubMed